In this video exclusive, Miguel Regueiro, MD, discussed a presentation from Digestive Disease Week on the impact of biologics on the prevalence of osteoporosis and bone fractures in patients with inflammatory bowel disease.

Regueiro, chair of the department of gastroenterology, hepatology and nutrition at Cleveland Clinic, said they found patients with IBD treated with biologics were less likely to have osteoporosis and bone fractures compared with those not on biologics.

Biologics may decrease the inflammation and cytokines, therefore improve bone health and reduce bone fractures, according to

Full Article: